Are These 2 Biotechs About to Be Bought?

This video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world.

In this video, David takes a closer look at two biotechs considered takeover targets. In fact, Amylin recently rebuffed an offer from Bristol-Myers Squibb. Will the large pharma come back with a stronger offer or will another player emerge from the shadows with a deal Amylin can't refuse? Meanwhile, Amarin recieved a patent for its cholesterol-fighting fish-oil-based drug AMR-101, which is pending FDA approval after two successful phase 3 trials. With patent protection in hand and potentially an approval on its way, will a deep-pocketed player with a thin pipeline step up to the plate, or will Amarin attempt to go it alone? Watch and find out.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time thisarticle was published David Williamson owns shares of Amarin plc (ADR). The Motley Fool owns shares of GlaxoSmithKline.Motley Fool newsletter services recommendGlaxoSmithKline. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.